Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
DAPZURA RT (DAPTOMYCIN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
DAPZURA RT
NDA
Get alerts
DAPTOMYCIN | N213645 | BAXTER HEALTHCARE CORP
5 strengths
1 unique patent
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
1 unique patent by expiration date
All strengths
500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
350MG/50ML (7MG/ML)
500MG/50ML (10MG/ML)
700MG/100ML (7MG/ML)
1GM/100ML (10MG/ML)
Active (1)
Today
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
11173189
Mar. 11, 2041
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (5)
Sort:
Name
↑
Applicant
Strength
Approval
#002 — 350MG/50ML (7MG/ML)
RLD
0 patents
0 exclusivities
▾
SOLUTION;INTRAVENOUS | Approved: Feb 27, 2023
#003 — 500MG/50ML (10MG/ML)
RLD
0 patents
0 exclusivities
▾
SOLUTION;INTRAVENOUS | Approved: Feb 27, 2023
#004 — 700MG/100ML (7MG/ML)
RLD
0 patents
0 exclusivities
▾
SOLUTION;INTRAVENOUS | Approved: Feb 27, 2023
#005 — 1GM/100ML (10MG/ML)
RLD
0 patents
0 exclusivities
▾
SOLUTION;INTRAVENOUS | Approved: Feb 27, 2023
#001 — 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
1 patent
0 exclusivities
▴
POWDER;INTRAVENOUS | Approved: Jan 25, 2022
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11173189
Mar 11, 2041
—
—
Yes
U-3294
METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL
—